I-MAB (IMAB)

• Market cap: $75.2M
• 1 day: -3.17%
• 5 days: -7.70%
• 1 month: -5.82%
• 3 months: -14.54%
• 6 months: -45.38%
• Year to date: -58.98%
• 1 year: -38.87%
• 5 years: -92.62%
• 10 years: -92.62%

About: I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).

Employees: 220

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

900% more call options, than puts

Call options by funds: $70K | Put options by funds: $7K

0.52% less ownership

Funds ownership: 8.15% [Q2] → 7.63% (-0.52%) [Q3]

17% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 6

26% less funds holding

Funds holding: 38 [Q2] → 28 (-10) [Q3]

31% less capital invested

Capital invested by funds: $25.4M [Q2] → $17.6M (-$7.75M) [Q3]

71% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 14

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $8 767% upside
• Avg. target: $8 767% upside
• High target: $8 767% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Andrew Fein 32% 1-year accuracy 105 / 327 met price target

767% upside $8

Buy Reiterated

15 Nov 2024